Trials / Completed
CompletedNCT02855775
Monoclonal Antibodies Elimination in Breast Cancer Patient
Study of the Relative Impact of the Neonatal Fc Receptor (FcRn) and the Therapeutic History on Monoclonal Antibodies Elimination. Proof of the Concept on Patients Treated by Bevacizumab or Trastuzumab in Breast Cancer
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Besancon · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This Study evaluates covariables being able to potentially influence the elimination of the monoclonal antibodies (trastuzumab, bevacizumab and denosumab).
Detailed description
Monoclonal antibodies are very widely used in cancer treatment . Certain patients benefit from these antibodies for several years and it is conceivable to wonder about the evolution of the pharmacokinetics of these antibodies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | additional blood sample | blood sample every 3 weeks |
Timeline
- Start date
- 2013-09-25
- Primary completion
- 2020-10-15
- Completion
- 2020-10-15
- First posted
- 2016-08-04
- Last updated
- 2021-04-19
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02855775. Inclusion in this directory is not an endorsement.